RESUMEN
Intestinal fibrosis is a common complication that affects more than 50% of Crohn´s Disease (CD) patients. There is no pharmacological treatment against this complication, with surgery being the only option. Due to the unknown role of P2X7 in intestinal fibrosis, we aim to analyze the relevance of this receptor in CD complications. Surgical resections from CD and non-Inflammatory Bowel Disease (IBD) patients were obtained. Intestinal fibrosis was induced with two different murine models: heterotopic transplant model and chronic-DSS colitis in wild-type and P2X7-/- mice. Human small intestine fibroblasts (HSIFs) were transfected with an siRNA against P2X7 and treated with TGF-ß. A gene and protein expression of P2X7 receptor was significantly increased in CD compared to non-IBD patients. The lack of P2X7 in mice provoked an enhanced collagen deposition and increased expression of several profibrotic markers in both murine models of intestinal fibrosis. Furthermore, P2X7-/- mice exhibited a higher expression of proinflammatory cytokines and a lower expression of M2 macrophage markers. Moreover, the transient silencing of the P2X7 receptor in HSIFs significantly induced the expression of Col1a1 and potentiated the expression of Col4 and Col5a1 after TGF-ß treatment. P2X7 regulates collagen expression in human intestinal fibroblasts, while the lack of this receptor aggravates intestinal fibrosis.
Asunto(s)
Fibroblastos , Intestinos , Receptores Purinérgicos P2X7 , Animales , Humanos , Ratones , Colitis/metabolismo , Colitis/patología , Colágeno/genética , Enfermedad de Crohn/metabolismo , Enfermedad de Crohn/patología , Fibroblastos/metabolismo , Intestinos/metabolismo , Receptores Purinérgicos P2X7/metabolismo , Factor de Crecimiento Transformador beta/farmacologíaAsunto(s)
Productos Biológicos/uso terapéutico , Psoriasis/complicaciones , Trombosis/etiología , Vasculitis/tratamiento farmacológico , Animales , Comunicación Celular/efectos de los fármacos , Células Endoteliales/efectos de los fármacos , Células Endoteliales/fisiología , Humanos , Imiquimod/farmacología , Leucocitos/efectos de los fármacos , Leucocitos/fisiología , Ratones , Psoriasis/inducido químicamente , Psoriasis/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidoresRESUMEN
Background: Vitamin D signaling modulates inflammation through the vitamin D receptor (VDR). The synonymous single nucleotide polymorphism (SNP) rs731236, located in the VDR gene, has been associated with a higher risk of Crohn's disease (CD). We analyzed differences in VDR expression levels among CD patients who were homozygous for allelic variants in this SNP and their relevance for disease course. Methods: DNA was extracted from blood samples of CD patients, and SNP genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism. Fresh blood from patients was used to isolate peripheral blood mononuclear cells (PBMCs) or to determine the expression of adhesion molecules by flow cytometry. We analyzed the gene expression of VDR and several cytokines in PBMCs using real-time polymerase chain reaction and the protein levels of VDR, NFκB, and IκBα by immunoblot. In addition, we collected complete clinical data for a group of 103 patients, including age at diagnosis, disease location, and disease behavior to compare patient characteristics with respect to genotype. Results: We found that CD patients who were homozygous for the risk allele presented lower levels of VDR protein in PBMCs, and that this was associated with an upregulation of IL1ß mRNA and activation of lymphocytic adhesion molecules. These patients had a higher risk of developing a B3-penetrating phenotype and of needing to undergo surgery. Conclusion: Our data highlight the relevance of vitamin D/VDR signaling in modulating the subjacent inflammation that leads to CD-related complications.
Asunto(s)
Enfermedad de Crohn/genética , Interleucina-1beta/metabolismo , Polimorfismo de Nucleótido Simple , Receptores de Calcitriol/genética , Adolescente , Adulto , Alelos , Estudios de Casos y Controles , Femenino , Homocigoto , Humanos , Interleucina-1beta/genética , Masculino , Polimorfismo de Longitud del Fragmento de Restricción , Adulto JovenRESUMEN
NSAIDs inhibit tumorigenesis in gastrointestinal tissues and have been proposed as coadjuvant agents to chemotherapy. The ability of cancer epithelial cells to adapt to the tumour environment and to resist cytotoxic agents seems to depend on rescue mechanisms such as autophagy. In the present study we aimed to determine whether an NSAID with sensitizing properties such as indomethacin modulates autophagy in gastric cancer epithelial cells. We observed that indomethacin causes lysosomal dysfunction in AGS cells and promotes the accumulation of autophagy substrates without altering mTOR activity. Indomethacin enhanced the inhibitory effects of the lysosomotropic agent chloroquine on lysosome activity and autophagy, but lacked any effect when both functions were maximally reduced with another lysosome inhibitor (bafilomycin B1). Indomethacin, alone and in combination with chloroquine, also hindered the autophagic flux stimulated by the antineoplastic drug oxaliplatin and enhanced its toxic effect, increasing the rate of apoptosis/necrosis and undermining cell viability. In summary, our results indicate that indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes and, by doing so, increases the sensitivity of gastric cancer cells to cytotoxic agents, an effect that could be used to overcome cancer cell resistance to antineoplastic regimes.
Asunto(s)
Adenocarcinoma/fisiopatología , Antiinflamatorios no Esteroideos/farmacología , Antineoplásicos/farmacología , Autofagia/efectos de los fármacos , Resistencia a Antineoplásicos/efectos de los fármacos , Indometacina/farmacología , Lisosomas/efectos de los fármacos , Oxaliplatino/farmacología , Neoplasias Gástricas/fisiopatología , Análisis de Varianza , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Cloroquina/metabolismo , Sinergismo Farmacológico , Humanos , Lisosomas/metabolismo , Macrólidos/metabolismoRESUMEN
BACKGROUND AND AIMS: Fibrosis is a common complication of Crohn's disease [CD], and is related to dysregulated tissular repair following inflammation, in which macrophages play a central role. We have previously observed that STAT6-/- mice present delayed mucosal recovery after 2,4,6-trinitrobenzenesulfonic acid [TNBS]-induced colitis due to a deficiency in reparatory interleukin-4 [IL4]/STAT6-dependent M2 macrophages, which can be reverted by the exogenous transfer of this cell type. In the present study, we analyse the role of STAT6-dependent macrophages in intestinal fibrosis. METHODS: Colitis was induced by weekly intra-rectal administration of TNBS [6 weeks] to STAT6-/- mice and wild-type [WT] animals. Colonic surgical resections were obtained from CD patients and from colon cancer patients. RESULTS: Chronic colitis provoked a fibrogenic response in STAT6-/- mice, but not in WT animals. An accumulation of M2 macrophages, defined as CD206+ cells, was observed in WT mice, but not in STAT6-/- animals. Instead, the latter group showed an increase in CD16+ macrophages that correlated with the expression of fibrogenic markers. CD16+ macrophages were also increased in the damaged mucosa of Crohn's disease patients with stenotic or penetrating complications. Finally, administration of IL4-treated WT macrophages to STAT6-/- mice reduced TNBS-induced fibrosis. CONCLUSIONS: Our study demonstrates that STAT6 deficiency dysregulates the macrophage response to inflammatory outbursts by increasing the presence of a population of CD16+ macrophages that seems to contribute to intestinal fibrosis.
Asunto(s)
Colitis/complicaciones , Neoplasias del Colon/patología , Enfermedad de Crohn/patología , Fibrosis/genética , Mucosa Intestinal/patología , Macrófagos/patología , Factor de Transcripción STAT6/genética , Adolescente , Adulto , Animales , Recuento de Células , Células Cultivadas , Colitis/inducido químicamente , Colitis/metabolismo , Colon/metabolismo , Colon/patología , Femenino , Fibrosis/etiología , Humanos , Interleucina-4/farmacología , Mucosa Intestinal/metabolismo , Lectinas Tipo C/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Masculino , Receptor de Manosa , Lectinas de Unión a Manosa/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Proteínas Proto-Oncogénicas/metabolismo , Receptores de Superficie Celular/metabolismo , Receptores de IgG , Ácido Trinitrobencenosulfónico , Proteínas Wnt/metabolismo , Adulto JovenRESUMEN
Introducción: La infección por el virus de la hepatitis C (VHC) es una de las principales causas de enfermedad hepática a nivel mundial. Alrededor de 60-80 por ciento de los infectados sufren una infección crónica pudiendo desarrollar otras patologías hepáticas como cirrosis y hepatocarcinoma. El tratamiento contra el VHC ha experimentado un enorme avance en la última década, cuya culminación ha llegado con la aparición de los Agentes Antivirales Directos (AAD) que han conseguido obtener tasas de curación superiores a 90 por ciento. Objetivo: Describir los diferentes mecanismos de acción de los AAD, además de contrastar los principales ensayos clínicos que están actualmente en desarrollo, hacer recomendaciones acerca de las opciones de tratamiento disponibles y perfilar los cambios que van a tener lugar en el tratamiento farmacológico de la Hepatitis C. Material y Métodos: Se realizaron varias búsquedas sistemáticas en la base de datos Pubmed, en los artículos expuestos en el Congreso The liver meeting en noviembre de 2014 de la AASLD (American Association for the Study of Liver Diseases), así como en la guía de la EASL (European Association for the Study of the Liver). Desarrollo: La llegada de nuevos fármacos con nuevas estrategias terapéuticas están incrementando la complejidad de la terapia, por ello es necesario conocer estos nuevos fármacos y sus posibles combinaciones. Conclusiones: Los excelentes resultados de la terapia con AAD han producido un intenso cambio en las recomendaciones terapéuticas, al permitir terapias de menor duración, mejor toleradas y de mayor seguridad(AU)
Introduction: The infection by the Hepatitis C virus (HCV) is one of the most common causes of liver's disease worldwide. Approximately between 60-80% of infected people, infection becomes chronic, and can lead in the long-term to the development of other liver's diseases such as cirrhosis and the hepatocellular carcinoma. Treatment of HCV has progressed enormously in the last decade, concluding with the development of Direct-acting Antiviral Agents (DAA), which has achieved cure rates over 90 percent. Objective: To know the different available treatments options as well as which will be available in a near future. Materials and methods: Several systematic searches were made in the PubMed database; in the articles from the liver meeting congress of AASLD (American Association for the Study of Liver Diseases) in November 2014 and in the EASL (European Association for the Study of Liver) guide. Development: The arrivals of new drugs with new therapeutic strategies have made this therapy more complex, and for that reason it is necessary to have knowledge of these drugs and their possible combinations. Conclusions: The excellent results of the therapy with AAD have made a huge change in therapeutic recommendations, making possible shorter therapies, better tolerated by patients and safer for health(AU)
Asunto(s)
Antivirales/uso terapéutico , Hepatitis C Crónica/prevención & control , Hepatitis C Crónica/tratamiento farmacológicoRESUMEN
BACKGROUND: Aspirin (ASA) causes gastrotoxicity by hampering the epithelial defense against luminal contents through cyclooxygenase inhibition. Since cell survival in tough conditions may depend on rescue mechanisms like autophagy, we analyzed whether epithelial cells rely on this process to defend themselves from aspirin's damaging action. METHODS: Rats received a single dose of ASA (150 mg/kg, p.o.) with or without pretreatment with the autophagy inhibitor 3-methyladenine, and gastric injury and epithelial autophagy were evaluated 3 h later. The effects of ASA on cell viability and autophagy were also evaluated in gastric epithelial AGS cells. RESULTS: Basal autophagy in the gastric mucosa was inhibited by ASA as demonstrated by increased levels of p62 and ubiquitinated proteins and total LC3 and a reduced LC3-II/LC3-I ratio. Similarly, ASA increased p62 and decreased LC3-II accumulation and the number of EmGFP/LC3B puncta in AGS cells. ASA activated the PI3K/Akt-GSK3-mTOR pathway, which phosphorylates ULK1 to prevent autophagy initiation, changes that were inhibited by the PI3K-inhibitor wortmannin. Autophagy inhibition seems to enhance the vulnerability of gastric epithelial cells as a combination of ASA with 3-methyladenine exacerbated rat gastric damage and AGS cell apoptosis. CONCLUSIONS: Our data highlight the importance of autophagy in the gastric mucosa as a protective mechanism when the epithelium is injured. In the stomach, aspirin induces mucosal damage and reduces autophagy, thus, eliminating a protective mechanism that epithelial cells could use to escape death. We hypothesize that the combination of aspirin with drugs that activate autophagy could protect against gastric damage.
Asunto(s)
Aspirina/farmacología , Autofagia/efectos de los fármacos , Inhibidores de la Ciclooxigenasa/farmacología , Células Epiteliales/efectos de los fármacos , Mucosa Gástrica/efectos de los fármacos , Animales , Aspirina/efectos adversos , Supervivencia Celular/efectos de los fármacos , Inhibidores de la Ciclooxigenasa/efectos adversos , Femenino , Mucosa Gástrica/patología , Masculino , Ratones Endogámicos BALB C , Ratas , Ratas Sprague-DawleyRESUMEN
El presente documento de consenso revisa la evidencia sobre evaluación de fármacos biológicos. Las conclusiones principales del grupo son: a) la evidencia actual sobre comparación de biológicos se basa en comparaciones indirectas y es, en general, poco fiable y con importantes limitaciones metodológicas; por ello, b) se considera necesario modificar las directivas regulatorias en el sentido de favorecer decididamente los estudios aleatorizados de no inferioridad comparando cara a cara los nuevos biológicos con los actuales estándares de tratamiento, evitando los ensayos frente a placebo; c) un elemento clave en este proceso será la determinación por consenso entre las agencias reguladoras, las sociedades científicas, la industria farmacéutica y las autoridades sanitarias de las diferencias clínicas que deben considerarse relevantes en cada una de las patologías evaluadas (AU)
This consensus document reviews the evidence on the evaluation of biological drugs. The main conclusions of the group are: a) the current evidence on biological comparisons is based on indirect comparisons and is generally unreliable and with important methodological limitations. Therefore, b) it is considered necessary to amend the regulatory directives in the sense of strongly favoring randomized non-inferiority studies comparing face to face the new biological treatment with current standards, avoiding trials versus placebo, c) a key element in this process will be determined by consensus among regulatory agencies, scientific societies, the pharmaceutical industry and health authorities regarding the clinical differences that should be considered relevant in each of the conditions tested (AU)
Asunto(s)
Humanos , Masculino , Femenino , Terapia Biológica/métodos , Terapia Biológica , Psoriasis/tratamiento farmacológico , Metaanálisis como Asunto , Quimioterapia/tendencias , Quimioterapia , Efectividad Biológica Relativa , Eficacia , Resultado del Tratamiento , Evaluación de Eficacia-Efectividad de IntervencionesRESUMEN
This consensus document reviews the evidence on the evaluation of biological drugs. The main conclusions of the group are: a) the current evidence on biological comparisons is based on indirect comparisons and is generally unreliable and with important methodological limitations. Therefore, b) it is considered necessary to amend the regulatory directives in the sense of strongly favoring randomized non-inferiority studies comparing face to face the new biological treatment with current standards, avoiding trials versus placebo, c) A key element in this process will be determined by consensus among regulatory agencies, scientific societies, the pharmaceutical industry and health authorities regarding the clinical differences that should be considered relevant in each of the conditions tested.
Asunto(s)
Productos Biológicos , Investigación sobre la Eficacia Comparativa/métodos , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Investigación sobre la Eficacia Comparativa/ética , Industria Farmacéutica , HumanosRESUMEN
Macrophage infiltration is a negative prognostic factor for most cancers but gastrointestinal tumors seem to be an exception. The effect of macrophages on cancer progression depends on their phenotype, which may vary between M1 (pro-inflammatory, defensive) to M2 (tolerogenic, pro-tumoral). Gastrointestinal cancers often become an ectopic source of gastrins and macrophages present receptors for these peptides. The aim of the present study is to analyze whether gastrins can affect the pattern of macrophage infiltration in colorectal tumors. We have evaluated the relationship between gastrin expression and the pattern of macrophage infiltration in samples from colorectal cancer and the influence of these peptides on the phenotype of macrophages differentiated from human peripheral monocytes in vitro. The total number of macrophages (CD68+ cells) was similar in tumoral and normal surrounding tissue, but the number of M2 macrophages (CD206+ cells) was significantly higher in the tumor. However, the number of these tumor-associated M2 macrophages correlated negatively with the immunoreactivity for gastrin peptides in tumor epithelial cells. Macrophages differentiated from human peripheral monocytes in the presence of progastrin showed lower levels of M2-markers (CD206, IL10) with normal amounts of M1-markers (CD86, IL12). Progastrin induced similar effects in mature macrophages treated with IL4 to obtain a M2-phenotype or with LPS plus IFNγ to generate M1-macrophages. Macrophages differentiated in the presence of progastrin presented a reduced expression of Wnt ligands and decreased the number and increased cell death of co-cultured colorectal cancer epithelial cells. Our results suggest that progastrin inhibits the acquisition of a M2-phenotype in human macrophages. This effect exerted on tumor associated macrophages may modulate cancer progression and should be taken into account when analyzing the therapeutic value of gastrin immunoneutralization.
Asunto(s)
Neoplasias del Colon/inmunología , Neoplasias del Colon/metabolismo , Gastrinas/metabolismo , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Activación de Macrófagos/inmunología , Macrófagos/inmunología , Macrófagos/metabolismo , Precursores de Proteínas/metabolismo , Anciano , Anciano de 80 o más Años , Recuento de Células , Línea Celular Tumoral , Neoplasias del Colon/patología , Femenino , Humanos , Inmunohistoquímica , Mucosa Intestinal/patología , Ligandos , Masculino , Persona de Mediana Edad , Clasificación del Tumor , Estadificación de Neoplasias , Fenotipo , Proteínas Wnt/metabolismoRESUMEN
Gastric mucosal inflammation is frequently associated with hypergastrinemia, and a correlation exists between the level of gastrin and degree of gastritis. We have previously observed that gastrin promotes leukocyte-endothelial interactions and contributes to Helicobacter-induced inflammation in the rat mesentery. In the present study, we aimed to evaluate a possible proinflammatory activity of gastrin in humans. The interaction between human leukocytes [U-937 cells, peripheral blood polymorphonuclear (PMN), and peripheral blood mononuclear (PBMC) cells] and human umbilical vein endothelial cells (HUVEC) was analyzed in static and dynamic conditions. The endothelial expression of adhesion molecules [P-selectin, E-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule (VCAM)-1] was analyzed by flow cytometry and fluorescent microscopy screening. Gastrin increased the static adhesion of U-937 cells to HUVEC (1 h; 10(-9) M: 122 +/- 9%; 10(-8) M: 143 +/- 17%; 10(-7) M: 162 +/- 14% vs. control, all P < 0.05). Incubation of HUVEC with gastrin (4 h) also increased PBMC rolling (vehicle: 63 +/- 12; 10(-9) M: 109 +/- 29; 10(-8) M: 141 +/- 24; 10(-7) M: 261 +/- 16 leukocytes/min, P < 0.05) and adhesion (vehicle: 3 +/- 2, 10(-9) M: 11 +/- 4, 10(-8) M: 17 +/- 5, 10(-7) M: 15 +/- 5 leukocytes/mm(2), all P < 0.05) in the parallel-plate flow chamber. Treatment of PBMC with gastrin had no effects. The cholecystokinin (CCK)-2 receptor antagonist (L-365,260, 10(-7) M) prevented the effects of gastrin. P-selectin and VCAM-1 expression were enhanced by gastrin, and neutralizing antibodies against these molecules prevented PBMC rolling and adhesion. Gastrin did not affect the interactions between HUVEC and PMN. Gastrin induces interactions between human mononuclear leukocytes and endothelial cells through the activation of CCK-2 receptors and the enhancement of endothelial P-selectin and VCAM-1.
Asunto(s)
Comunicación Celular/fisiología , Células Endoteliales/fisiología , Gastrinas/farmacología , Leucocitos Mononucleares/fisiología , Selectina-P/metabolismo , Molécula 1 de Adhesión Celular Vascular/metabolismo , Adhesión Celular/efectos de los fármacos , Comunicación Celular/efectos de los fármacos , Células Cultivadas , Citometría de Flujo , Humanos , Rodamiento de Leucocito/efectos de los fármacos , Microscopía Fluorescente , Receptor de Colecistoquinina B/metabolismo , Venas Umbilicales/citologíaRESUMEN
A single intraperitoneal injection of endotoxin (40 microg/kg) significantly delayed gastric emptying of a solid nutrient meal. Blockade of nitric oxide synthase (NOS) with 30 mg/kg ip N(G)-nitro-L-arginine methyl ester or 20 mg/kg ip 7-nitroindazole [neuronal NOS (nNOS) inhibitor] significantly delayed gastric emptying in control animals but failed to modify gastric emptying in endotoxin-treated rats. Administration of 2.5, 5, and 10 mg/kg ip N(6)-iminoethyl-L-lysine [inducible NOS (iNOS) inhibitor] had no effect in either experimental group. Indomethacin (5 mg/kg sc), NS-398 (cyclooxygenase-2 inhibitor; 10 mg/kg ip), and dexamethasone (10 mg/kg sc) but not quinacrine (20 mg/kg ip) significantly prevented delay in gastric emptying induced by endotoxin but failed to modify gastric emptying in vehicle-treated animals. Ca(2+)-dependent NOS activity in the antrum pylorus of the stomach was diminished by endotoxin, whereas Ca(2+)-independent NOS activity was not changed. In addition, decreased nNOS mRNA and protein were observed in the antrum pylorus of endotoxin-treated rats. Our results suggest that downregulation of nNOS in the antrum pylorus of the stomach and synthesis of prostaglandins mediate the delay in gastric emptying of a solid nutrient meal induced by endotoxin.